Investigating the essential roles of Ubiquitin-like molecules and the Ubiquitin Proteasome System


GSK has a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer.

The R&D campus at Tres Cantos is fully integrated with the global GSK R&D organisation and combines a molecular discovery research facility, a drug discovery centre focused on diseases of the developing world as well as pre-clinical and clinical teams.

The molecular discovery facility is equipped to provide early discovery services, holds one of the two Automated Liquid Stores with the GSK compound collection and represents half of GSK’s capacity for high throughput screening. Its scientific teams have 20 years of experience in design and development of biochemical and cellular assays, execution of screening campaigns and biological profiling of hits and leads for all therapeutic areas.

The Centre for Diseases of the Developing World is strongly aligned with GSK’s commitment to accelerate its contribution to the global effort to control and eliminate neglected tropical diseases. It is focused on malaria, tuberculosis, leishmaniasis, Chagas disease and sleeping sickness. With an Open Source philosophy, the DDW puts the information it generates in the public domain. In addition to its experienced scientific teams, the campus welcomes and sponsors scientists from all over the world working on these diseases through the Open Lab initiative.



Nitin Jindal